Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
View in:
PubMed
subject areas
Aged
Aged
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Anticoagulants
Anticoagulants
Arthroplasty, Replacement, Knee
Arthroplasty, Replacement, Knee
Blood Coagulation
Blood Coagulation
Double-Blind Method
Double-Blind Method
Factor Xa Inhibitors
Factor Xa Inhibitors
Female
Female
Hemorrhage
Hemorrhage
Humans
Humans
Infusions, Intravenous
Infusions, Intravenous
Male
Male
Middle Aged
Middle Aged
Pyrazoles
Pyrazoles
Pyridones
Pyridones
Thrombin
Thrombin
Thrombin Time
Thrombin Time
Time Factors
Time Factors
Treatment Outcome
Treatment Outcome
Venous Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Venous Thrombosis
authors with profiles
Gary E Raskob